Views on Cipla - Launches the Pulmicort Respules 1mg /ml generic version: Angel Broking

Views of Ms. Sarabjit Kour Nangra (VP Research - Pharma, Angel Broking)

Cipla- Launches the Pulmicort Respules 1mg /ml generic version:

"Cipla launched asthma treatment medicine- Pulmicort Respules the generic version, in partnership with Sandoz. Pulmicort Respules (1mg /ml version) is used for long-term treatment and prevention of asthma. Cipla has 180 day exclusivity with Sandoz for the medicine. Branded sales of the drug stands at US$ 242mn in the US market. Sandoz and Cipla are the only companies that have approval for 1 mg/ml version of Pulmicort Respules. Cipla can generate around US$ 20-30mn sales in FY2016, during the 180 day exclusivity period. Since the drug will not make significant impact on the earnings, we maintain our EPS numbers and NEUTRAL rating on the stock."

Shares of CIPLA LTD. was last trading in BSE at Rs.709.2 as compared to the previous close of Rs. 710.1. The total number of shares traded during the day was 151555 in over 3683 trades.

The stock hit an intraday high of Rs. 724.75 and intraday low of 706.3. The net turnover during the day was Rs. 108398854.

Source : Equity Bulls

Keywords